ImportRefusal LogoImportRefusal

Glaxo Smithkline Brazil

⚠️ Moderate Risk

FEI: 3004051362 • Rio de Janeiro, Rio de Janeiro • BRAZIL

FEI

FEI Number

3004051362

📍

Location

Rio de Janeiro, Rio de Janeiro

🇧🇷

Country

BRAZIL
🏢

Address

Estrada Bandeirantes 8464, , Rio de Janeiro, Rio de Janeiro, Brazil

Moderate Risk

FDA Import Risk Assessment

40.3
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

1
Total Refusals
1
Unique Violations
7/5/2003
Latest Refusal
7/5/2003
Earliest Refusal

Score Breakdown

Violation Severity
90.0×40%
Refusal Volume
11.2×30%
Recency
0.0×20%
Frequency
10.0×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

751×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
7/5/2003
62FCP99ANTI-INFECTIVE, TOPICAL N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)

Frequently Asked Questions

What is Glaxo Smithkline Brazil's FDA import refusal history?

Glaxo Smithkline Brazil (FEI: 3004051362) has 1 FDA import refusal record(s) in our database, spanning from 7/5/2003 to 7/5/2003.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Glaxo Smithkline Brazil's FEI number is 3004051362.

What types of violations has Glaxo Smithkline Brazil received?

Glaxo Smithkline Brazil has been cited for 1 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Glaxo Smithkline Brazil come from?

All FDA import refusal data for Glaxo Smithkline Brazil is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.